# US 2012/0251553 A1 · Biomarkers for schizophrenia or other psychotic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251553 A1
- Document ID: US20120251553A1
- Status: Published application
- Kind: A1
- Application number: 13/395,283
- Filed: 2010-09-09
- Published: 2012-10-04
- Earliest claimed: 2009-09-09
- Assignees: Psynova Neurotech Ltd.
- Inventors: Sabine Bahn; Yishai Levin
- Web page: https://patentgrep.com/patent/US20120251553A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- G01N 2800/302: Schizophrenia
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A method of aiding in diagnosing schizophrenia or other psychotic disorder, or predisposition thereto, in an individual suspected of having schizophrenia, comprising:
(a) quantifying the amount of Synaptotagmin-10 in a biological sample from the individual suspected of having schizophrenia; and
(b) communicating the amount of Synaptotagmin-10 to the individual's health care provider.

### Claim 27 (depends on 26)

The method of claim 26, further comprising:
(c) quantifying the amount, in the biological sample from the individual suspected of having schizophrenia, of one or more second analytes selected from: Homeobox protein Hox-C13, WD repeat containing protein 19, Ig lambda chain C regions, Complement C6, Fibroleukin, Multidrug resistance-associated protein 9, Zinc finger protein castor homolog 1, Heparin cofactor 2, AP-3 complex subunit delta-1, Myosin-XVIIIa, Enhancer of polycomb homolog 1, FYVE or WH2 domain-containing protein 1; and
(d) communicating the amount of the one or more second analytes to the individual's health care provider.

### Claim 28 (depends on 27)

The method of claim 27, further comprising:
(e) quantifying the amount, in the biological sample from the individual suspected of having schizophrenia, of one or more third analytes selected from: Beta-2-glycoprotein 1, Sorting nexin-17, Chromodomain-helicase-DNA-binding protein 3, Serum amyloid P-component, Antithrombin-III, Serine/Threonine-protein kinase TAO3, Keratin or Kinesin-like protein; and
(f) communicating the amount of the one or more third analytes to the individual's health care provider.

### Claim 29 (depends on 26)

The method of claim 26, wherein quantifying the amount of Synaptotagmin-10 is performed using a Synaptotagmin-10 ligand.

### Claim 30 (depends on 26)

The method of claim 26, wherein quantifying the amount of Synaptotagmin-10 is performed using a biosensor or a microanalytical, microengineered, microseparation or immunochromatography system.

### Claim 31 (depends on 26)

The method of claim 26, wherein quantifying the amount of Synaptotagmin-10 is performed using an immunological method.

### Claim 32 (depends on 26)

The method of claim 26, wherein quantifying the amount of Synaptotagmin-10 is performed using one or more methods selected from: mass spectrometry, chromatography, or gel-based analysis.

### Claim 33 (depends on 32)

The method of claim 32, wherein quantifying the amount of Synaptotagmin-10 is performed using one or more methods selected from:
Surface-enhanced laser desorption/ionization, Matrix-assisted laser desorption/ionization, a 1-D gel-based analysis, a 2-D gel-based analysis, reverse phase chromatograpy, size permeation chromatograpy, ion exchange chromatograpy, affinity chromatograpy, High Performance Liquid Chromatography, or Ultra Performance Liquid Chromatography.

### Claim 34 (depends on 26)

The method of claim 26, wherein the biological sample is cerebrospinal fluid, whole blood, blood serum, plasma, urine, saliva, or other bodily fluid, or breath, condensed breath, or an extract or purification therefrom, or dilution thereof.

### Claim 35 (depends on 26)

The method of claim 26, further comprising:
(c) comparing the amount of Synaptotagmin-10 in the biological sample with the amount present in one or more control biological samples; and
(d) communicating to the individual's health care provider that a difference exists between the amount of Synaptotagmin-10 in the biological sample and the amount present in the one or more control biological samples, which is indicative of schizophrenia or other psychotic disorder, or predisposition thereto.

### Claim 36

A method treating schizophrenia in an individual suspected of having schizophrenia, comprising;
(a) obtaining data indicating that a difference exists between the amount of Synaptotagmin-10 in a first biological sample from the individual suspected of having schizophrenia and the amount present in one or more control biological samples; and
(b) treating the individual for schizophrenia.

### Claim 37 (depends on 36)

The method of claim 36, further comprising obtaining data indicating that a difference exists between the amount of one or more second analytes in the biological sample from the individual suspected of having schizophrenia and the amount present in one or more control biological samples, wherein the one or more second analytes are selected from: Homeobox protein Hox-C13, WD repeat containing protein 19, Ig lambda chain C regions, Complement C6, Fibroleukin, Multidrug resistance-associated protein 9, Zinc finger protein castor homolog 1, Heparin cofactor 2, AP-3 complex subunit delta-1, Myosin-XVIIIa, Enhancer of polycomb homolog 1, FYVE or WH2 domain-containing protein 1.

### Claim 38 (depends on 37)

The method of claim 37, further comprising obtaining data indicating that a difference exists between the amount of one or more third analytes in the biological sample from the individual suspected of having schizophrenia and the amount present in one or more control biological samples, wherein the one or more third analytes are selected from: Beta-2-glycoprotein 1, Sorting nexin-17, Chromodomain-helicase-DNA-binding protein 3, Serum amyloid P-component, Antithrombin-III, Serine/Threonine-protein kinase TAO3, Keratin or Kinesin-like protein.

### Claim 39 (depends on 36)

The method of claim 36, further comprising comparing the amount of Synaptotagmin-10 in the biological sample with the amount present in one or more control biological samples.

### Claim 40 (depends on 36)

The method of claim 36, wherein treating the individual for schizophrenia comprises administering one or more antipsychotic drugs to the individual.

### Claim 41 (depends on 36)

The method of claim 36, further comprising:
(c) monitoring the efficacy of treatment.

### Claim 42 (depends on 41)

The method of claim 41, wherein monitoring the efficacy of treatment comprises obtaining data indicating that a difference exists between the amount of Synaptotagmin-10 in the first biological sample from the individual suspected of having schizophrenia and the amount present in a second biological sample taken after the beginning of treatment.

### Claim 43 (depends on 36)

The method of claim 36, further comprising quantifying the amount of Synaptotagmin-10 in the first biological sample from the individual suspected of having schizophrenia.

### Claim 44

A kit for aiding in diagnosing schizophrenia or other psychotic disorder, or predisposition thereto, in an individual suspected of having schizophrenia, comprising:
(a) two or more ligands of two or more analytes selected from: Synaptotagmin-10 Homeobox protein Hox-C13, WD repeat containing protein 19, Ig lambda chain C regions, Complement C6, Fibroleukin, Multidrug resistance-associated protein 9, Zinc finger protein castor homolog 1, Heparin cofactor 2, AP-3 complex subunit delta-1, Myosin-XVIIIa, Enhancer of polycomb homolog 1, FYVE, WH2 domain-containing protein 1, Beta-2-glycoprotein 1, Sorting nexin-17, Chromodomain-helicase-DNA-binding protein 3, Serum amyloid P-component, Antithrombin-III, Serine/Threonine-protein kinase TAO3, Keratin or Kinesin-like protein; and
(b) instructions for quantifying the amount of the two or more analytes in a biological sample using the two or more ligands.

### Claim 45 (depends on 44)

The kit of claim 44, wherein a first ligand is a ligand of Synaptotagmin-10.

### Claim 46 (depends on 45)

The kit of claim 45, wherein a second ligand is a ligand of an analyte selected from: Homeobox protein Hox-C13, WD repeat containing protein 19, Ig lambda chain C regions, Complement C6, Fibroleukin, Multidrug resistance-associated protein 9, Zinc finger protein castor homolog 1, Heparin cofactor 2, AP-3 complex subunit delta-1, Myosin-XVIIIa, Enhancer of polycomb homolog 1, FYVE or WH2 domain-containing protein 1.

### Claim 47 (depends on 46)

The kit of claim 46, wherein a third ligand is a ligand of an analyte selected from: Beta-2-glycoprotein 1, Sorting nexin-17, Chromodomain-helicase-DNA-binding protein 3, Serum amyloid P-component, Antithrombin-III, Serine/Threonine-protein kinase TAO3, Keratin or Kinesin-like protein.

### Claim 48 (depends on 44)

The kit of claim 44, further comprising a listing of the amount of the two or more analytes in one or more control biological samples and the amount of the two or more analytes in one or more biological samples of individuals with schizophrenia.
